Press release
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:\n\n\nPiper Sandler 36th Annual Healthcare Conference – December 3-5, 2024\n\n\nType: Fireside Chat Presentation\nDate/Time: December 3, 2024, 1:30 p.m. EST\n\n\n7th Annual Evercore ISI HealthCONx Conference – December 3-5, 2024\n\n\nType: Fireside Chat Presentation\nDate/Time: December 4, 2024, 2:10 p.m. EST\n\n\nThe APA/JPS/CAP/IAP 2024 Joint Meeting – December 9-12, 2024\n\n\nTitle: PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)\nDate/Time: December 9, 2024, 12:00 p.m. HST\nPresenter: Eleonora Goldberg\nSession: Poster\n\n\nRNA at the Bench and Bedside IV – December 9-11, 2024\n\n\nTitle: Developing siRNA for Neurodegenerative Disorders\nDate/Time: December 9, 2024, 2:10 p.m. PST\nPresenter: Christine Esau\nSession: Pre-clinical RNA Therapeutics\n\n\n21st Global CVCT Forum – December 9-11, 2024\n\n\nTitle: A Randomized, Placebo-Controlled Phase 3 Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome\nDate/Time: December 10, 2024, 7:30 p.m. EST\nPresenter: Jennifer Hellawell and Robert Rosenson\nSession: Attended Poster Viewing Session and Oral Presentation\n\n\n8th Complement-Based Drug Development Summit – December 10-11, 2024\n\n\nTitle: Targeting Complement C3 and Factor B with siRNA: Concept to Clinic\nDate/Time: December 11, 2024, 10:00 a.m. EST\nPresenter: James Hamilton\nSession: Advancing Complement Therapies: Pathways, Clinical Insights & Future Directions\n\n\n22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) – December 12-14, 2024\n\n\nTitle: PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in Adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)\nDate/Time: December 13, 2024, 7:30-9:00 a.m. PST\nPresenter: Nick Leeper and Ira Goldberg\nSession: Poster and Abstract Oral Presentation Session\n\n\nPresentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.\n\n\nAbout Arrowhead Phar...